<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Routine monitoring of children and adolescents with type 1 diabetes for complications</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Routine monitoring of children and adolescents with type 1 diabetes for complications</h1>
<div class="graphic"><div class="figure"><div class="ttl">Routine monitoring of children and adolescents with type 1 diabetes for complications</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Evaluation</td> <td class="subtitle1">Purpose</td> <td class="subtitle1">Initiate screening</td> <td class="subtitle1">Repeat at least</td> <td class="subtitle1">Abnormal result</td> <td class="subtitle1">Usual treatment</td> </tr> <tr class="divider_bottom"> <td><strong>Hypoglycemia assessment</strong></td> <td>Ask about episodes of hypoglycemia and associated symptoms, and review records of blood glucose monitoring. Evaluate for hypoglycemia unawareness.</td> <td>After diagnosis of diabetes.</td> <td>Every 3 months.</td> <td>Frequent episodes of hypoglycemia (blood glucose level &lt;70 mg/dL), especially with hypoglycemia unawareness.</td> <td>Review insulin and monitoring regimen, and educate regarding prevention of and response to hypoglycemia. Consider continuous glucose monitoring and automated insulin delivery systems.</td> </tr> <tr class="divider_bottom"> <td><strong>Psychosocial assessment</strong></td> <td> <p>Screen for depression, family conflict, risk-taking behaviors, or other psychosocial dysfunction.</p> <p>Offer time alone with clinician, starting at age 12 years when developmentally appropriate.</p> In older children and adolescents, screen for eating disorders, and provide anticipatory counseling and screen for smoking and use of e-cigarettes.</td> <td> <p>At diagnosis of diabetes.</p> <p>Assess for psychosocial and diabetes-related stress starting at 7 to 8 years of age.</p> Screen for eating disorders starting at 10 to 12 years of age.</td> <td>Every 3 months.</td> <td>Clinical symptoms of depression, eating disorder, or psychosocial dysfunction.</td> <td> <p>Refer to mental health professional.</p> <p>For youth who smoke or use e-cigarettes (vaping nicotine), provide counseling and/or referral for cessation assistance.</p> Preconception counseling for girls of childbearing potential starting at puberty.</td> </tr> <tr class="divider_bottom"> <td><strong>Smoking</strong></td> <td>Ask about use or experimentation with tobacco products including vaping (e-cigarettes).</td> <td>At initial diabetes visit.</td> <td>Every 3 months.</td> <td>History of smoking or vaping.</td> <td>Discourage smoking and vaping. If there is a history of smoking or vaping, encourage cessation.</td> </tr> <tr> <td class="divider_bottom" rowspan="2"><strong>BP</strong></td> <td class="divider_bottom" rowspan="2">Screen for hypertension.</td> <td class="divider_bottom" rowspan="2">At diagnosis of diabetes.</td> <td class="divider_bottom" rowspan="2">Every 3 months.</td> <td> Elevated BP <span class="nowrap_whitespace">(prehypertension)<sup>[1,2]</sup>:</span> <ul class="decimal_heading"> <li>&lt;13 years – BP ≥90 to <span class="nowrap_whitespace">95<sup>th</sup></span> percentile</li> <li>≥13 years – SBP 120 to 129 mmHg with DBP &lt;80 mmHg (measured on 3 occasions)</li> </ul> </td> <td> <p>Nonpharmacologic intervention (diet and exercise, with weight reduction if appropriate).</p> Initiate pharmacologic intervention (ACE inhibitor or ARB) if BP remains in prehypertensive range despite intervention for 3 to 6 months*.</td> </tr> <tr class="divider_bottom"> <td> Hypertension<sup>[1]</sup>: <ul class="decimal_heading"> <li>&lt;13 years – BP <span class="nowrap_whitespace">≥95<sup>th</sup></span> percentile for age, sex, and height</li> <li>≥13 years – BP ≥130/80 mmHg (measured on 3 occasions)</li> </ul> </td> <td>In addition to nonpharmacologic intervention, initiate pharmacologic intervention (ACE inhibitor or <span class="nowrap_whitespace">ARB)*<sup>[3]</sup>.</span></td> </tr> <tr class="divider_bottom"> <td><strong>Foot examination with testing for vibration (tuning fork) and pressure (10 g monofilament)</strong></td> <td>Screen for polyneuropathy.</td> <td>Age ≥10 years (or onset of puberty, if earlier) and if the youth has had diabetes for ≥5 years.</td> <td>Annually.</td> <td>Inspection, palpation of dorsalis pedis and posterior tibial pulses, assessment of vibration, proprioception and 10 g monofilament sensation.</td> <td>Optimize glycemic control with blood glucose monitoring and insulin administration (refer to topic text).</td> </tr> <tr class="divider_bottom"> <td><strong>Urine albumin:creatinine ratio (spot specimen)</strong></td> <td>Screen for nephropathy.</td> <td>Age ≥10 years (or onset of puberty, if earlier) and if the youth has had diabetes for ≥5 years.</td> <td>Annually.</td> <td>&gt;30 mg albumin/g creatinine (in at least 2 of 3 urine samples over a 6-month interval, following efforts to improve glycemic control and normalize <span class="nowrap_whitespace">BP)<sup>¶</sup>.</span></td> <td>ACE inhibitor or ARB*.</td> </tr> <tr class="divider_bottom"> <td><strong>A1C</strong></td> <td>Glycemic control.</td> <td>At diagnosis of diabetes.</td> <td>Every 3 months.</td> <td>Goal A1C &lt;7% for most children and <span class="nowrap_whitespace">adolescents<sup>Δ</sup><sup>[2]</sup>.</span></td> <td>Optimize glycemic control with blood glucose monitoring and insulin administration (refer to topic text).</td> </tr> <tr> <td class="divider_bottom" rowspan="3"><strong>Lipid profile</strong></td> <td class="divider_bottom" rowspan="3">Screen for dyslipidemia.</td> <td class="divider_bottom" rowspan="3"> <p>At diagnosis of diabetes, once initial glycemic control is achieved and age ≥2 <span class="nowrap_whitespace">years<sup>◊</sup>.</span></p> If sample was nonfasting (random) and results abnormal, confirm with a fasting lipid panel.</td> <td class="divider_bottom" rowspan="3">If initial LDL ≤100, initiate serial testing at age 9 to 11 years and repeat every 3 years if normal. Repeat annually if LDL is abnormal or if glycemic control is poor.</td> <td>LDL ≥100 mg/dL.</td> <td>Nonpharmacologic intervention: optimize glycemic control; exercise and diet to limit dietary cholesterol (≤200 mg/day) and saturated fat (≤7% of total calories) and maintain healthy body weight.</td> </tr> <tr> <td>LDL ≥130 to 159 mg/dL.</td> <td> <p>Pharmacologic intervention (statins) for children ≥10 years <strong>if</strong> any CVD risk factors are present (obesity, tobacco use, family history of early CVD), if nonpharmacologic intervention is not successful, and after reproductive counseling.</p> Aim for LDL ≤100 mg/dL.</td> </tr> <tr class="divider_bottom"> <td>LDL ≥160 mg/dL.</td> <td> <p>Pharmacologic intervention (statins) for children ≥10 years, if nonpharmacologic intervention is not successful, and after reproductive counseling.</p> Aim for LDL ≤100 mg/dL.</td> </tr> <tr class="divider_bottom"> <td><strong>TSH</strong></td> <td>Screen for hypothyroidism caused by autoimmune thyroiditis.</td> <td>At diagnosis of diabetes, after patient is clinically stable or soon after glycemic control is <span class="nowrap_whitespace">established<sup>◊</sup>.</span></td> <td>Every 1 to 2 years, or if symptoms of hypothyroidism develop, or if anti-thyroid antibodies are present.</td> <td>Elevated TSH.</td> <td>Treatment with levothyroxine as needed.</td> </tr> <tr class="divider_bottom"> <td><strong>tTG, IgA</strong></td> <td>Screen for celiac disease.</td> <td>At diagnosis of diabetes.</td> <td>Repeat within 2 years of diagnosis, then after 5 years, or if gastrointestinal symptoms develop, and more frequently if a first-degree relative has celiac <span class="nowrap_whitespace">disease<sup>§</sup>.</span></td> <td>Positive results of antibody test.</td> <td>Evaluate further with upper endoscopy, <strong>before</strong> beginning a gluten-free diet.</td> </tr> <tr> <td><strong>Dilated eye examination</strong></td> <td>Screen for retinopathy.</td> <td>Age ≥11 years (or onset of puberty, if earlier), and the child has had diabetes for 3 to 5 years.</td> <td>Repeat every 2 years. May be done less frequently based on risk factor assessment (including A1C ≤8%) and advice of an eye care professional.</td> <td>Background, preproliferative, or proliferative retinopathy.</td> <td>Optimizing glycemic control may reverse background retinopathy; laser therapy for more advanced disease.</td> </tr> </tbody></table></div><div class="graphic_lgnd">This table reflects recommendations for routine monitoring of children and adolescents with type 1 diabetes, as outlined by the <span class="nowrap_whitespace">ADA<sup>[1]</sup>.</span></div><div class="graphic_footnotes"><p>BP: blood pressure; 
        SBP: systolic blood pressure; 
        DBP: diastolic blood pressure; 
        ACE: angiotensin-converting enzyme; 
        ARB: angiotensin receptor blocker; 
        A1C: hemoglobin A1c (glycated hemoglobin); 
        LDL: low-density lipoprotein; 
        CVD: cardiovascular disease; 
        TSH: thyroid-stimulating hormone; 
        tTG: tissue transglutaminase; 
        IgA: immunoglobulin A; 
        ADA: American Diabetes Association; 
        TPO: thyroid peroxidase.</p>
<p>* ACE inhibitors (eg, lisinopril or enalapril) and ARBs have teratogenic potential, so appropriate reproductive counseling should be given to young women. Aim for BP consistently <span class="nowrap_whitespace">&lt;90<sup>th</sup></span> percentile for age, sex, and height.</p>
<p>¶ Transient albuminuria is common in children. Abnormal results should be confirmed on at least 2 occasions, ruling out orthostatic albuminuria, or with a 24-hour urine collection.</p>
<p>Δ More or less stringent goals may be appropriate for individual patients, depending on their personal history of severe hyperglycemia, severe hypoglycemia, and hypoglycemia unawareness.</p>
<p>◊ Glycemic control should be established before performing the lipid profile or thyroid screening. The ADA suggests that antibodies to TPO and thyroglobulin should be measured at diagnosis.</p>
    
    § More frequent screening for celiac disease may be appropriate for children who have a first-degree relative with celiac disease. Measurement of tTg is sufficient if IgA is normal. Antibody testing is only valid if performed on a gluten-containing diet.</div><div class="graphic_reference">References:
<ol>
<li>American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, et al. 14. Children and Adolescents: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022; 45:S208.</li>
<li>Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 2017; 140.</li>
<li>Bjornstad P, Dart A, Donaghue KC, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Microvascular and macrovascular complications in children and adolescents with diabetes. Pediatr Diabetes 2022; 23:1432.</li>
</ol></div><div id="graphicVersion">Graphic 97226 Version 17.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
